(RPID) Rapid Micro Biosystems - Ratings and Ratios

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) is a life sciences technology company specializing in microbial contamination detection solutions for pharmaceutical, medical device, and personal care product manufacturing. The companys Growth Direct platform automates and modernizes manual microbial quality control (MQC) testing workflows, addressing critical needs in biologics, vaccines, cell and gene therapies, and sterile injectables. The platform includes the Growth Direct system, proprietary consumables, lab information management system (LIMS) connection software, and comprehensive customer support and validation services. Additional offerings include RMBNucleus software, featuring mold detection alerts and a central manager portal for multi-instrument coordination. The company also provides environmental monitoring, water, bioburden, and sterility release testing solutions, along with onsite technical training services. Headquartered in Lowell, Massachusetts, Rapid Micro Biosystems was incorporated in 2006 and rebranded from Genomic Profiling Systems, Inc. in 2007. Web URL: https://www.rapidmicrobio.com

From a financial perspective, Rapid Micro Biosystems operates with a market capitalization of $131.25M USD and a price-to-sales ratio of 5.02, indicating a premium valuation relative to its revenue. The company currently trades at $2.47 per share, with a 20-day average volume of 1,060,654 shares. Its short-term moving averages (SMA 20: $3.07) suggest recent downward pressure, while the SMA 50 ($1.96) and SMA 200 ($1.14) reflect a broader bearish trend. The average true range (ATR) of 0.37 highlights moderate volatility. The companys return on equity (RoE) stands at -57.36%, reflecting significant losses. The lack of positive P/E and forward P/E ratios underscores ongoing profitability challenges.